Frequently Asked Questions

Find the answers to all your questions about EVO Visian ICL (EVO).

Search FAQs

The Implantable Collamer Lens for nearsightedness and astigmatism is a refractive lens also known as a phakic IOL. “Phakic” meaning that the natural lens of the eye is in place, and “IOL” meaning intraocular lens, or a lens inside the eye. The EVO Visian ICL is a posterior chamber implant that is introduced through a small incision in the eye and is placed behind the iris (the colored part of the eye), and in front of the natural crystalline lens in order to improve your nearsightedness and astigmatism.

The EVO Visian ICL Lens (EVO) is intended for the correction of moderate to high nearsightedness. EVO Visian ICL and EVO Visian TICL surgery is intended to safely and effectively correct nearsightedness between -3.0 D to -15.0 D, the reduction in nearsightedness up to -20.0 D and treatment of astigmatism from 1.0 D to 4.0 D. If you have nearsightedness within these ranges, EVO Visian ICL surgery may improve your distance vision without eyeglasses or contact lenses. Because the EVO Visian ICL corrects for distance vision, it does not eliminate the need for reading glasses, you may require them at some point, even if you have never worn them before.

EVO represents an alternative to other refractive surgeries including laser assisted in situ keratomileusis (LASIK), photorefractive keratectomy (PRK), incisional surgeries, or other means to correct myopia such as contact lenses and eyeglasses.

Patients who are pregnant and nursing and patients with a narrow angle in the front chamber of their eye, because in this case the space for the EVO lens would be too small. The patient education booklet provides an additional list of conditions that should be taken into consideration when making a decision about the EVO procedure.

Follow all of your eye care professional’s instructions before and after implantation of the EVO lens. Take any prescribed medication and schedule all recommended follow-up visits with your eye care professional, usually on an annual basis after the healing of the EVO surgery. Contact your eye care professional immediately if you should experience a problem.

The material is called Collamer®, a collagen co-polymer that contains a small amount of purified collagen which is proprietary to STAAR Surgical; the remainder is made of a similar material to that found in soft contact lenses. It is very biocompatible (does not cause a reaction inside the eye) and stable. It also contains an ultraviolet light filter.

Prior to being placed on the market, EVO was subject to extensive research and development. Today, more than 2,000,000 lenses have been implanted worldwide. In a US clinical study, over 99.4 percent of patients were satisfied with their implant. EVO has a track record of excellent clinical outcomes.

EVO is intended to remain in place without maintenance. EVO can be removed by your eye care professional if needed in the future. If your physician removes the EVO lens, you will lose the benefit of your nearsightedness correction.

No. EVO is positioned behind the iris (the colored part of the eye), where it is invisible to both you and others. Only your eye care practitioner will be able to tell that vision correction has taken place.

EVO is not typically noticeable after it is implanted. It does not attach to any structures within the eye and does not move around once in place.

The key benefit of EVO surgery is the permanent correction or reduction of your nearsightedness and treatment of astigmatism allowing you to see clearly at long distances without eyeglasses or contact lenses or reduce your dependence upon them. In addition to the improvement of your uncorrected vision (vision without eyeglasses or contact lenses), your best corrected vision (best vision with contact lenses/eye glasses) may be improved.

The EVO surgery is performed on an outpatient basis which means that the patient has surgery and leaves the same day. The procedure itself usually takes 20-30 minutes or less. The patient will need someone to drive them home on surgery day. A light, topical or local anesthetic is administered. There is very little discomfort during or after surgery. Some eye drops or medication may be prescribed and a visit with your eye care professional is usually scheduled the day after surgery.

Important Safety Information

The EVO Visian ICL Lens is intended for the correction of moderate to high nearsightedness. EVO Visian ICL and EVO Visian TICL surgery is intended to safely and effectively correct nearsightedness between -3.0 D to -15.0 D, the reduction in nearsightedness up to -20.0 D and treatment of astigmatism from 1.0 D to 4.0 D. If you have nearsightedness within these ranges, EVO Visian ICL surgery may improve your distance vision without eyeglasses or contact lenses. Because the EVO Visian ICL corrects for distance vision, it does not eliminate the need for reading glasses, you may require them at some point, even if you have never worn them before.

Implantation of the EVO Visian ICL is a surgical procedure, and as such, carries potentially serious risks. Please discuss the risks with your eye care professional. Complications, although rare, may include need for additional surgical procedures, inflammation, loss of cells from the back surface of the cornea, increase in eye pressure, and cataracts.

You should NOT have EVO Visian ICL surgery if:

  • Your doctor determines that the shape of your eye is not an appropriate fit for the EVO Visian ICL
  • You are pregnant or nursing
  • You have moderate to severe damage to the optic nerve caused by increased pressure (glaucoma)
  • You do not meet the minimum endothelial cell density for your age at the time of implantation as determined by your eye doctor
  • Your vision is not stable as determined by your eye doctor

Before considering EVO Visian ICL surgery you should have a complete eye examination and talk with your eye care professional about EVO Visian ICL surgery, especially the potential benefits, risks, and complications. You should discuss the time needed for healing after surgery. For additional information with potential benefits, risks and complications please visit DiscoverICL.com

References

Find a Doctor

References

1Patient Survey, STAAR Surgical ICL Data Registry, 2018

2Sanders D. Vukich JA. Comparison of implantable collamer lens (ICL) and laser-assisted in situ keratomileusis (LASIK) for Low Myopia. Cornea. 2006 Dec; 25(10):1139-46.

3Naves, J.S. Carracedo, G. Cacho-Babillo, I. Diadenosine Nucleotid Measurements as Dry-Eye Score in Patients After LASIK and ICL Surgery. Presented at American Society of Cataract and Refractive Surgery (ASCRS) 2012.

4Shoja, MR. Besharati, MR. Dry eye after LASIK for myopia: Incidence and risk factors. European Journal of Ophthalmology. 2007; 17(1): pp. 1-6.

5aLee, Jae Bum et al. Comparison of tear secretion and tear film instability after photorefractive keratectomy and laser in situ keratomileusis. Journal of Cataract & Refractive Surgery , Volume 26 , Issue 9 , 1326 - 1331.

5bParkhurst, G. Psolka, M. Kezirian, G. Phakic intraocular lens implantantion in United States military warfighters: A retrospective analysis of early clinical outcomes of the Visian ICL. J Refract Surg. 2011;27(7):473-481.

*American Refractive Surgery Council